ATE241970T1 - Kombinationen von formoterol und mometasonfuroat - Google Patents

Kombinationen von formoterol und mometasonfuroat

Info

Publication number
ATE241970T1
ATE241970T1 AT00910739T AT00910739T ATE241970T1 AT E241970 T1 ATE241970 T1 AT E241970T1 AT 00910739 T AT00910739 T AT 00910739T AT 00910739 T AT00910739 T AT 00910739T AT E241970 T1 ATE241970 T1 AT E241970T1
Authority
AT
Austria
Prior art keywords
formoterol
mometasone furoate
combinations
solvate
salt
Prior art date
Application number
AT00910739T
Other languages
English (en)
Inventor
Ian Francis Hassan
Jeremy Guy Clarke
Henry Luke Danahay
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10848904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE241970(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE241970T1 publication Critical patent/ATE241970T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00910739T 1999-03-03 2000-03-01 Kombinationen von formoterol und mometasonfuroat ATE241970T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9904919.9A GB9904919D0 (en) 1999-03-03 1999-03-03 Organic compounds
PCT/EP2000/001722 WO2000051591A1 (en) 1999-03-03 2000-03-01 Combinations of formoterol and mometasone furoate for asthma

Publications (1)

Publication Number Publication Date
ATE241970T1 true ATE241970T1 (de) 2003-06-15

Family

ID=10848904

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910739T ATE241970T1 (de) 1999-03-03 2000-03-01 Kombinationen von formoterol und mometasonfuroat

Country Status (27)

Country Link
US (4) US20020055494A1 (de)
EP (2) EP1156790B1 (de)
JP (3) JP2002538110A (de)
KR (1) KR100682418B1 (de)
CN (1) CN1196478C (de)
AT (1) ATE241970T1 (de)
AU (1) AU770739B2 (de)
BR (1) BR0008699A (de)
CA (1) CA2362499C (de)
CL (1) CL2004001170A1 (de)
CZ (1) CZ294089B6 (de)
DE (1) DE60003160T2 (de)
DK (1) DK1156790T3 (de)
ES (1) ES2200837T3 (de)
GB (1) GB9904919D0 (de)
HK (1) HK1043048B (de)
HU (1) HU229073B1 (de)
ID (1) ID30171A (de)
IL (1) IL144351A (de)
NO (1) NO331428B1 (de)
NZ (1) NZ513742A (de)
PL (1) PL212355B1 (de)
PT (1) PT1156790E (de)
RU (1) RU2270670C2 (de)
SK (1) SK286338B6 (de)
WO (1) WO2000051591A1 (de)
ZA (1) ZA200106442B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
ES2779273T3 (es) * 2002-03-01 2020-08-14 Chiesi Farm Spa Formulación superfina de formoterol
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1542904B1 (de) * 2002-08-27 2008-01-16 Schering Corporation Verfahren zur herstellung von dosierinhalatorformulierungen
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
AU2004285447A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical compositions
EP1680084A2 (de) * 2003-10-21 2006-07-19 Direct-Haler A/S Mehrrouten-medikament zur behandlung von rhinitis und asthma
WO2006105401A2 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2007059620A1 (en) * 2005-11-23 2007-05-31 Feanny Stephen J Method for administering formoterol using a nebulizer
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
US20080294720A1 (en) * 2007-05-21 2008-11-27 International Business Machines Corporation Enhanced Online Collaboration System
US8898316B2 (en) * 2007-05-30 2014-11-25 International Business Machines Corporation Enhanced online collaboration system for viewers of video presentations
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111926T3 (pl) * 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
EP2533765A2 (de) * 2010-01-29 2012-12-19 Mahmut Bilgic Pharmazeutische zusammensetzungen mit formoterol und mometason
EP2611416B1 (de) * 2010-09-03 2015-08-19 Pharmaterials Ltd. Pharmazeutische zubereitung zur verwendung in pulverinhalatoren
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
EA035755B1 (ru) * 2014-10-08 2020-08-05 Замбон С.П.А. Лекарственный препарат, содержащий будесонид и формотерол
AU2016364650B2 (en) 2015-12-04 2019-04-04 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN115813935A (zh) * 2021-09-16 2023-03-21 上海上药信谊药厂有限公司 药物组合物、气雾剂及其制备方法和气雾剂产生系统
CN116763797B (zh) * 2022-03-09 2025-09-02 上海医药工业研究院有限公司 一种药物组合微球、其制备方法及其原料组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
CZ288032B6 (cs) * 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
WO1996019198A1 (en) 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
IL131640A0 (en) * 1997-03-20 2001-01-28 Schering Corp Preparation of powder agglomerates
EP1033991B1 (de) * 1997-10-09 2002-04-17 Schering Corporation Mometasonfuroat-suspensionen zum zerstäuben
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma

Also Published As

Publication number Publication date
HK1043048A1 (en) 2002-09-06
DK1156790T3 (da) 2003-09-29
PT1156790E (pt) 2003-10-31
AU770739B2 (en) 2004-03-04
US7566705B2 (en) 2009-07-28
NO20013988L (no) 2001-08-16
AU3284300A (en) 2000-09-21
US20040105822A1 (en) 2004-06-03
HK1043048B (en) 2004-01-30
CA2362499A1 (en) 2000-09-08
ZA200106442B (en) 2002-09-05
CL2004001170A1 (es) 2005-03-28
JP5663046B2 (ja) 2015-02-04
CN1196478C (zh) 2005-04-13
NO20013988D0 (no) 2001-08-16
RU2270670C2 (ru) 2006-02-27
JP2010001295A (ja) 2010-01-07
ID30171A (id) 2001-11-08
IL144351A (en) 2005-12-18
CZ20013168A3 (cs) 2001-12-12
HUP0200142A2 (en) 2002-06-29
WO2000051591A1 (en) 2000-09-08
PL212355B1 (pl) 2012-09-28
SK12302001A3 (sk) 2001-12-03
BR0008699A (pt) 2001-12-26
EP1156790B1 (de) 2003-06-04
US20020055494A1 (en) 2002-05-09
CN1341017A (zh) 2002-03-20
ES2200837T3 (es) 2004-03-16
EP1156790A1 (de) 2001-11-28
CZ294089B6 (cs) 2004-10-13
DE60003160D1 (de) 2003-07-10
GB9904919D0 (en) 1999-04-28
JP5646828B2 (ja) 2014-12-24
IL144351A0 (en) 2002-05-23
DE60003160T2 (de) 2004-05-19
NZ513742A (en) 2001-09-28
SK286338B6 (en) 2008-07-07
EP1325765A1 (de) 2003-07-09
CA2362499C (en) 2009-01-27
KR20010102473A (ko) 2001-11-15
US20030050290A1 (en) 2003-03-13
US20060009437A1 (en) 2006-01-12
KR100682418B1 (ko) 2007-02-15
JP2002538110A (ja) 2002-11-12
US7067502B2 (en) 2006-06-27
NO331428B1 (no) 2011-12-27
JP2013067668A (ja) 2013-04-18
HU229073B1 (en) 2013-07-29

Similar Documents

Publication Publication Date Title
ATE241970T1 (de) Kombinationen von formoterol und mometasonfuroat
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
MY126768A (en) Combinations of formoterol and fluticasone propionate for asthma
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
MX9200992A (es) Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
ATE99941T1 (de) Medikamente enthaltend salmeterol und fluticason.
DK2105143T3 (da) Lægemiddelsammensætninger baseret på tiotropiumsalte og ciclesonid
SE9704644D0 (sv) New use
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
BR122014030158B8 (pt) formulação farmacêutica
TH49369A (th) การรวมกันของบีตา-2-อะกอนิสท์และสเทอรอยด์

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1156790

Country of ref document: EP